U.S. markets closed

Annovis Bio, Inc. (ANVS)

NYSE - NYSE Delayed Price. Currency in USD
10.36+0.18 (+1.77%)
At close: 04:00PM EST
10.36 0.00 (0.00%)
After hours: 05:46PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close10.18
Bid10.37 x 1000
Ask11.00 x 1000
Day's Range9.97 - 10.48
52 Week Range5.42 - 23.89
Avg. Volume327,520
Market Cap109.608M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-4.93
Earnings DateApr 01, 2024 - Apr 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ANVS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Annovis Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 10/14/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease

    MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease (AD). "The completion of the Alzheimer’s study marks a significant step in our efforts to bring new therapies to patients,” said Maria Maccecchini, Ph.D., Founder, Presid

  • InvestorPlace

    3 Growth Stocks to Sell in February Before They Bottom

    February triggered a rollercoaster ride through the stock market’s twists and turns. Amidst the cacophony of growth stocks to sell, three names echo the market with a hint of fundamental caution. Once labeled castles of value potential, these growth stocks stand at a dangerous crossroads. From the bustling aisles of automotive retail to the lofty heights of aerospace and defense and the promising frontiers of biotechnology, each sector carries its tale of uncertainty. Discover the allure of grow

  • GlobeNewswire

    Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio

    MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications. This application follows the U.S. Provisional Application No. 63/440,890 which was filed on January 24, 2023. The patent application titled “Treatment of Mental Illness via Admi